Pleiotropic effects of statin therapy: molecular mechanisms and clinical results

Chao Yung Wang, Ping-Yen Liu, James K. Liao

Research output: Contribution to journalReview article

403 Citations (Scopus)

Abstract

Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels. However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such as Rho, Rac and Cdc42. Therefore, it is possible that statins might exert cholesterol-independent or 'pleiotropic' effects through direct inhibition of these small GTP-binding proteins. Recent studies have shown that statins might have important roles in diseases that are not mediated by cholesterol. Here, we review data from recent clinical trials that support the concept of statin pleiotropy and provide a rationale for their clinical importance.

Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalTrends in Molecular Medicine
Volume14
Issue number1
DOIs
Publication statusPublished - 2008 Jan 1

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cholesterol
Oxidoreductases
Therapeutics
Terpenes
Primary Prevention
Secondary Prevention
GTP-Binding Proteins
Cardiovascular Diseases
Clinical Trials
Lipids
Enzymes
Serum

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology

Cite this

@article{7e13b2234bed4178a0e1467d04bb6db9,
title = "Pleiotropic effects of statin therapy: molecular mechanisms and clinical results",
abstract = "Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels. However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such as Rho, Rac and Cdc42. Therefore, it is possible that statins might exert cholesterol-independent or 'pleiotropic' effects through direct inhibition of these small GTP-binding proteins. Recent studies have shown that statins might have important roles in diseases that are not mediated by cholesterol. Here, we review data from recent clinical trials that support the concept of statin pleiotropy and provide a rationale for their clinical importance.",
author = "Wang, {Chao Yung} and Ping-Yen Liu and Liao, {James K.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.molmed.2007.11.004",
language = "English",
volume = "14",
pages = "37--44",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "1",

}

Pleiotropic effects of statin therapy : molecular mechanisms and clinical results. / Wang, Chao Yung; Liu, Ping-Yen; Liao, James K.

In: Trends in Molecular Medicine, Vol. 14, No. 1, 01.01.2008, p. 37-44.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pleiotropic effects of statin therapy

T2 - molecular mechanisms and clinical results

AU - Wang, Chao Yung

AU - Liu, Ping-Yen

AU - Liao, James K.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels. However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such as Rho, Rac and Cdc42. Therefore, it is possible that statins might exert cholesterol-independent or 'pleiotropic' effects through direct inhibition of these small GTP-binding proteins. Recent studies have shown that statins might have important roles in diseases that are not mediated by cholesterol. Here, we review data from recent clinical trials that support the concept of statin pleiotropy and provide a rationale for their clinical importance.

AB - Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels. However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such as Rho, Rac and Cdc42. Therefore, it is possible that statins might exert cholesterol-independent or 'pleiotropic' effects through direct inhibition of these small GTP-binding proteins. Recent studies have shown that statins might have important roles in diseases that are not mediated by cholesterol. Here, we review data from recent clinical trials that support the concept of statin pleiotropy and provide a rationale for their clinical importance.

UR - http://www.scopus.com/inward/record.url?scp=38049034068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049034068&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2007.11.004

DO - 10.1016/j.molmed.2007.11.004

M3 - Review article

C2 - 18068482

AN - SCOPUS:38049034068

VL - 14

SP - 37

EP - 44

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 1

ER -